For the Inventor, By the Inventor

Enter assignee name

Malvern, PA, United States of America

Phasebio Pharmaceuticals, Inc.

USPTO Granted Patents = 12

CIPO Patents = 2

EPO Patents = 6

Trademarks = 1

Forward Citations = 32

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Susan Arnold (6 out of 6 patents)

Lynne Georgopoulos (5 out of 5 patents)

David James Ballance (4 out of 5 patents)

4. Suzanne Dagher (3 out of 7 patents)

5. Christopher M Yates (2 out of 46 patents)

6. Steven Sparks (2 out of 7 patents)

7. Andrew J Turner (2 out of 15 patents)

8. Homayoun Sadeghi (2 out of 2 patents)

9. Sammy Ray Shaver (2 out of 31 patents)

10. James Jowett (1 out of 1 patent)

11. Christopher Prior (1 out of 1 patent)

12. William Joel Hoekstra (1 out of 81 patents)

13. Lynne M Georgopoulos (0 patent)

14. Lynne M Georgopoulos (0 patent)

15. Andrew Turner (0 patent)

12 patents: Sort by Forward Citations

1. 11266719 - Methods and compositions for treating muscle disease and disorders (2022-03-08),

2. 11136309 - Metalloenzyme inhibitor compounds (2021-10-05),

3. 11052132 - Methods and compositions for treating cystic fibrosis (2021-07-06),

4. 11040034 - Metalloenzyme inhibitor compounds (2021-06-22),

5. 10940182 - Use of modified vasoactive intestinal peptides in the treatment of hypertension (2021-03-09),

6. 10722590 - ELP fusion proteins for controlled and sustained release (2020-07-28),

7. 10688156 - Methods and compositions for treating muscle disease and disorders (2020-06-23),

8. 9919032 - Method for administering a sustained release formulation (2018-03-20),

9. 9700598 - Modified vasoactive intestinal peptides (2017-07-11),

10. 9561262 - Use of modified vasoactive intestinal peptides in the treatment of hypertension (2017-02-07),

11. 9029505 - Modified vasoactive intestinal peptides (2015-05-12),

12. 7709227 - Multimeric ELP fusion constructs (2010-05-04),

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new therapies for the treatment of orphan diseases and cardiopulmonary indications. With a strong emphasis on innovative science, the company aims to develop novel, bioengineered compounds that address unmet medical needs. PhaseBio's pipeline includes potential treatments for severe cardiopulmonary conditions and rare genetic disorders, with a vision to improve patients' lives and transform healthcare.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

12 Patents

#32 in Malvern, PA

#928 in Pennsylvania

#25,526 in US

#48,090 in the World

Malvern, PA, United States of America

Phasebio Pharmaceuticals, Inc.

Forward Citations = 32

12 inventors:

Susan Arnold (6 out of 6 patents)

Lynne Georgopoulos (5 out of 5 patents)

David James Ballance (4 out of 5 patents)

4. Suzanne Dagher (3 out of 7 patents)

5. Christopher M Yates (2 out of 46 patents)

Please report any incorrect information to [email protected]

Loading…